|
|
|
|
Science Sparks @ ACTREC
|
02 November 2026 |
Vol. No. 15 ; Issue No.759 |
|
|
Publications
|
|
1. Joshi R, Nath S, Gupta S (2026). Telomere Dynamics in Congenital Heart Defects: Hidden Architects of Cardiogenesis? Human Mutation
2. Maddirala H, Siva M, Kumari S (2026). Primary malignant vaginal melanoma-navigating rarity, aggressiveness and therapeutic uncertainty. BMJ Case Reports. 19(10):e274596
3. Gillessen S, Turco F, Davis ID, Efstathiou JA, Emmett L... Murthy V, Mutambirwa SBA, Nguyen PL, O'Sullivan JM...etal (2026) Management of Patients with High-risk Localised, Locally Advanced, and Biochemically Recurrent Prostate Cancer: Report from the 2026 Advanced Prostate Cancer Consensus Conference. European Urology.
4. Khurud P, Munshi A, Wadasadawala T (2026). Commentary on: Postmastectomy chest-wall irradiation effects on 10-year survival in early breast cancer. Journal of Cancer Research and Therapeutics. 22(5):996-998.
5. Sekar A, Rekhi B, Ghosh J, Menon S, Shetty O, Deodhar K, Rath S, Mittal N, Mehta A, Gulia S, Maheshwari A, Chopra S, Gupta S (2026). A retrospective analysis of BCOR-immunohistochemistry positive uterine sarcomas: Clinical features and survival. Journal of Cancer Research and Therapeutics. 22(5):884-891.
6. Kazi M, Reddy KS, Sharma A, De Souza A, Saklani A (2026). Patterns and predictors of relapse following cytoreductive surgery for Pseudomyxoma Peritonei. Journal of Surgical Oncology.
7. Hande V, Ndarukwa S, Rubio AP, Berger D, Anacak Y, Sucharski M, Flores JAS, Agarwal JP, Msadabwe SC, Gamboa E, Mwaiselage JD, Vanchinbazar E, Sanaa EM, Batyrkanova C, Shami A, Alanyali S, Sabaddin NA, Sukhin V, Jaksic B, Tamaki T, Chopra S (2026). Implementing Image-Guided Brachytherapy (IGBT) For Cervical Cancer in Resource-Limited Settings: An International Multicentric Cross-Sectional Study of Resource and Workflow Impact. International Journal of Radiation Oncology, Biology, Physics.
8. Prakash G, Gota V, Sharma D, Chopra S, Pal M, Arora A, Nagarajan R, Misra A, Bakshi G, Murthy V, Maitre P, Gurram L, Mittal P, Patwardhan R, Checker R, Joshi M, Madki S, Gupta S, Kumar S, Bonkar Dethe S, Gawad P, Ghadge S, Menon S, Ghanty T, Kannan S, Badwe R, Chaturvedi P, Gupta S, Sandur S (2026). Phase II Non-Randomised Trial of Oral Chlorophyllin in Haemorrhagic Cystitis from Radiation Therapy (CLARITY Trial): clinical and quality-of-life outcomes with exploratory proteomics. Scientific Reports.
Book Chapter
1. Shettigar A, Fernandes L, Bal M, Prabhash K, Chandrani P. (2026). Oncogene-Driven Thyroid Cancer and Its Therapeutic Implications. In:Kostoglou-Athanassiou I(Ed.), Thyroid Cancer - Novel Aspects in Pathogenesis and Treatment Oncology. IntechOpen. ISBN: (978-1-80631-181-1)
Proceedings Publication
1. Poladia P, Tupe R, Chavan P, Naresh C, Pagdhune A (2026). From data to quality: Using Six Sigma to assess lab performance. In: Proceedings of the Conference on Bioengineering for Global Health (SYMRESEARCH 2.0 2025). Advances in Biological Sciences Research. Vol.55
|
|
|
|
|
Interesting Reads
|
|
Pérol M, Yoshida T, Ahn MJ, Gay CM, Schuler M, Liu H, Sezer A, Bilici A, Korantzis I, Lim SM, Otsubo K, Juan-Vidal O, Chen Y, Schvartsman G, Wang H, Dingemans AC, Clarke JM, Desai A, Marigil M, Chen Y, Abidi B, Wang J, Sands J; DeLLphi-305 Investigators (2026). Tarlatamab-Durvalumab Maintenance for Extensive-Stage Small-Cell Lung Cancer. New England Journal of Medicine.
|
|
|
Video of the Week
|
|
| Health Policy and Cancer |
|
| |
|
|
| |
|
|
|
|
Do You Know?
In 2001, Results of a clinical trial showed that the drug imatinib mesylate, which targets a unique protein produced by the Philadelphia chromosome, is effective against chronic myelogenous leukemia (CML).
|
|
|
|
Cancer News
|
| |
|
|
| |
|
|
|
A metabolic–epigenetic pathway drives immune suppression in colorectal cancer
|
|
Nature Cancer, 28/10/2026
|
|
Tumor-associated neutrophils are being recognized as regulators of cancer immune evasion but the pathways that drive their pathogenic states remain unclear. A study now reveals a metabolic–chromatin crosstalk via a GSK3β–FH–fumarate–KDM2B axis that epigenetically reprograms neutrophils...
|
|
|
|
|
|
|
|
|
2026 Advanced Centre for Treatment, Research and Education in Cancer (ACTREC)
|
|